Ireland
--:--IST
Active, not recruiting Not applicable

The Effects of Astaxanthin on Physiological Anti-fatigue and Sports Performance: an Integrated Study From the Application of Laboratory Human Sports Platform to Simulated Competitions

NCT07630870 · tracked via the Priya Life Science China tracker
Phase
Not applicable
Started
2025-08-01
Last updated
2026-08-10

Condition(s) studied

Healthy

Investigational drug(s) / intervention(s)

PlaceboAstaxanthin

Placebo: Supplemented with placebo for 4 weeks

Astaxanthin: Supplemented with Astaxanthin (AST) for 4 weeks (12 mg/day, AstaReal®, Sweden)

Study summary

To address the rapid recovery needs in intensive badminton competitions, this 2-year study evaluates Astaxanthin (AST) as a potential ergogenic aid. The research aims to elucidate how AST attenuates exercise-induced oxidative stress, inflammation, and muscle damage. By establishing an evidence-based nutritional strategy, this study seeks to maintain peak performance for elite athletes in badminton and other racket sports, while supporting the development of functional anti-fatigue health products.

Eligibility

Sex
ALL
Min age
18 Years
Max age
35 Years
Healthy volunteers
Accepted
Inclusion Criteria: * A minimum of five years of badminton training experience (with a training frequency of at least three times per week, sustained for three consecutive years). Exclusion Criteria: * chronic diseases, such as heart disease or hypertension, drinking habits and severe lower limb musculoskeletal injuries within the past six months.

Primary outcome measure(s)

  • Badminton specific incremental endurance test — Baseline,week 1 end of 4-week supplementation period
    The badminton specific incremental endurance test measures endurance performance through repetitive specific movements on a Y-shaped court layout (3-meter distance between points). Unit of Measure: Minutes

Trial sites (1)

FacilityCityRegionStatus
China Medical University Taichung Taiwan
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07630870 on ClinicalTrials.gov ↗ ← All trials in China